An observational study in Diffuse Large B-cell Lymphoma, sponsored by Zhao Weili. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-01.
Sponsored by Zhao Weili · Observational
To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.
This study retrospectively collected the data of patients previously treated with Tafa and divided them into two coords according to different protocols received. Cohort 1 was Tafa combined treatment group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitor, Tafa combined with Lenalidomide plus chemotherapy (including ADC). Cohort 2 was treated with sequential CAR T or graft after Tafa combination therapy.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's planned enrollment of 15 is below the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →Zhao Weili is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Recurrent or refractory diffuse large B-cell lymphoma after systemic therapy
Exclusion Criteria:
Tafa combination therapy group, which could include Tafa combined with lenalidomide, Tafa combined with Lenalidomide plus BTK inhibitors, Tafa combined with Lenalidomide plus chemotherapy (including ADC)
Drug: Tafasitamab Injection
Tafa combination therapy group followed by sequential CAR T or transplantation
Drug: Tafasitamab Injection
The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
Also known as: lenalidomide
objective remission rate
Defined as the proportion of patients with CR and PR
Time frame: at the end of Cycle 2 (each cycle is 28 days)
Progression-free survival (PFS)
The time between the start of treatment and when the tumor progresses or the patient dies
Time frame: 1year after induction therapy
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhao Weili